Special Issue "Cancer and Humoral Immunity"
Deadline for manuscript submissions: 20 October 2022 | Viewed by 287
Interests: B cell responses in cancer; antibody engineering and glycoengineering; IgE class of antibodies in cancer; antibody Fc-mediated functions in cancer; cancer immunology; cancer immunotherapy; antibody-drug conjugates; melanoma; ovarian cancer; breast cancer; allergo-oncology; ADCC; ADCP; macrophages; monocytes; NK cells
Special Issues, Collections and Topics in MDPI journals
A better understanding of the role of B cells in orchestrating an antitumor response has the potential to broaden the efficacy of immunotherapy for patients with advanced cancer. While the role of T cells in cancer immunology has been studied extensively, a fulsome understanding of B cell populations and effector mechanisms mediating humoral immunity against cancer has not been carefully elucidated. Although many causal mechanisms of humoral antitumor immunity have not yet been described, strong positive correlations between B cells and cancer-specific survival and response to therapy have recently been reported. Many studies have demonstrated that the presence of intratumoral B cells is strongly associated with survival in several histologies, including sarcoma, melanoma, lung, and colorectal cancer. This Special issue will summarize several topics related to humoral antitumor immunity, including the dual role of B cells in promoting and inhibiting cancer, the antitumor functions of B cells such as antibody-dependent cell cytotoxicity, mechanisms of tumor-antigen presentation by B cells, the importance of cancer-associated tertiary lymphoid structures, and the impact of immunoglobin repertoire and isotype on cancer immunosurveillance. Finally, we will assemble an up-to-date review on recent advances in developing B cell-based immunotherapies and vaccines for the treatment of advanced cancers.
Prof. Dr. Sophia Karagiannis
Dr. Joseph G Crompton
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer and B cells
- humoral antitumor immunity
- cancer-associated tertiary lymphoid structures